Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
5(100.0%)
5Total
Phase 3(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01198834Phase 3Completed

MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains

Role: lead

NCT01968005Phase 3Completed

Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain

Role: lead

NCT01161615Phase 3Completed

MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder

Role: lead

NCT01506154Phase 3Completed

Safety & Efficacy Study of MRX-7EAT Patch in the Treatment of Pain of the Shoulder

Role: lead

NCT02695381Phase 3Completed

Etodolac-lidocaine Patch in Subjects Experiencing Acute Delayed Onset Muscle Soreness

Role: lead

All 5 trials loaded